Drug Discovery World

AUGUST 1, 2023

Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Drugs 130

Drugs Licensing Licensing Engineering 130

Drug Target Review

SEPTEMBER 5, 2024

This role gave me a good understanding of how important IP/patent and global marketing are for the brand but also the importance of emerging markets and co-development and out-licensing to other pharma companies. I experienced challenges in cultural differences working with US, UK, Japan, and China.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

Drug Discovery World

FEBRUARY 19, 2024

We’re also seeing that the valuation of companies is dropping, opening the door for larger pharmaceutical companies to step in and make acquisitions. The transformative impact of gene therapy, particularly for paediatric and neurodegenerative conditions, cannot be overstated.

Drug Development 147

Drug Development Small Molecule Drugs Therapies 147

The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.

Drug Development 80

Drug Development Clinical Trials Drugs Therapies 80

The Pharma Data

OCTOBER 9, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. 2 PsA can be a challenging disease to treat especially in younger populations, reinforcing the need for additional treatment options. A decision from the U.S.

FDA Approval 52

FDA Approval FDA Treatment Pharmaceutical Companies 52

The Pharma Data

DECEMBER 16, 2020

–( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc. NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical Co.,

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

Drug Discovery World

JULY 2, 2024

Many of the more recent companies to launch in Switzerland have grown out of, developed assets from, or received financial support from the established pharmaceutical corporations in the country. For example, biotechs Actelion and Light Chain Bioscience/Novimmune were both started by Roche scientists. References [link] [link].

Science 147

Science Drugs Clinical Trials Licensing 147

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

Drug Discovery World

SEPTEMBER 14, 2023

As the second quarter of 2023 draws to a close, DDW’s Megan Thomas reviews key updates and results from three top pharmaceutical companies. In July 2023, AstraZeneca and Ionis Pharmaceuticals expanded their existing collaboration on eplontersen to also include Latin America. billion, a decrease of $15.0

Vaccine 147

Vaccine FDA Approval Drugs Licensing 147

Drug Discovery World

AUGUST 3, 2023

For example, the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition to date 1. Even still, these approved drug products require a licensed healthcare provider’s prescription.

Clinical Trials 130

Clinical Trials Regulations Production FDA 130

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Pharmaceuticals 40

Pharmaceuticals Licensing Licensing Clinical Trials 40

Drug Discovery World

MARCH 7, 2023

She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Dr Janette Thomas, CEO, Five Alarm Bio Five Alarm Bio is an anti-ageing therapeutics company, which completed a seed investment round in early 2023.

International 246

International Science Pharmaceuticals DNA 246

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

JANUARY 15, 2021

January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. The study evaluated Darzalex Faspro® in combination with VCd, compared with VCd alone, a common treatment regimen used in adult patients with newly diagnosed AL amyloidosis.[5] Comenzo, M.D., Director, John C.

FDA Approval 52

FDA Approval FDA Treatment Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

Drug Target Review

SEPTEMBER 19, 2024

It has a well-defined and strategically focused R&D pipeline of innovative treatments targeting various stages of Parkinson’s as they worsen over time. The pipeline currently includes five drug candidates, all of which have the potential to revolutionise the treatment of PD.

Disease 52

Disease Drugs Treatment Drug Development 52

The Pharma Data

JANUARY 27, 2021

28, 2021 /PRNewswire/ — CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.). “The responses observed in six out of nine patients are very encouraging and clearly suggest that BI-1206 may restore the response to rituximab in patients who have few treatment alternatives. and BEIJING , Jan.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Crown Bioscience

MAY 4, 2021

Why are cancer treatments for children lagging behind the latest advancements in clinical oncology? used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children. Each year approximately 400,000 children from infants to teenagers are diagnosed with cancer worldwide.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

FEBRUARY 12, 2022

“As a global pharmaceutical company, Lilly has worked hard to fight this pandemic. “With the emergence of variants such as Omicron, treatment options remain limited. . “With the emergence of variants such as Omicron, treatment options remain limited.

Treatment 40

Treatment Hospitals FDA Clinical Trials 40

Drug Discovery World

OCTOBER 16, 2023

The campus is home to GSK, the Cell and Gene Therapy Manufacturing Catapult, LifeArc and Cytiva, alongside a growing cluster of start-up companies which together have raised £2.9 Next, Saleko highligts how Northumberland and the North East of the UK are recognised for pharmaceutical manufacturing prowess. billion in funding.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

MARCH 4, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) and Ovid Therapeutics Inc. Our goal is to one day bring new treatment options that provide greater seizure control, tolerability and function to DS and LGS patients around the world.”. Advancing New Treatment Options for DS and LGS Patients.

Treatment 52

Treatment Pharmaceutical Companies Clinical Trials Licensing 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Ricks , Lilly chairman and CEO.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

APRIL 22, 2023

While the obesity pandemic grows, especially amongst low-income communities, effective medical treatments remain inaccessible for millions in need. Such high prices make it challenging for millions of people to afford the medications and obtain access to treatment. Yet that is simply not possible, nor will it ever be.

Medical Schools 40

Medical Schools Licensing Licensing Treatment 40

The Pharma Data

JULY 29, 2021

HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Following our successful partnership to form Phathom Pharmaceuticals, we are extremely pleased to partner again with Takeda to form HilleVax,” said Tachi Yamada, M.D., About Takeda Pharmaceutical Company Limited.

Vaccine 52

Vaccine Pharmaceutical Companies Clinical Trials Virus 52

The Pharma Data

FEBRUARY 22, 2021

Under the terms of the settlement agreements, AbbVie and Medytox will release all claims against Evolus related to the alleged misappropriation of Medytox’s trade secrets and grant a license to Evolus to continue to commercialize Jeuveau® in the United States and Nuceiva in all other territories in which Evolus has licensing rights.

Licensing 40

Licensing Licensing Pharmaceutical Companies Pharmaceuticals 40

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. The Company’s validated, proprietary F.I.R.S.T

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

JANUARY 25, 2021

26, 2021 /PRNewswire/ — Asieris Pharmaceuticals announced today that the company has entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to exclusively register and commercialize Hexvix® in Mainland China and Taiwan. SHANGHAI , Jan. Founder and CEO of Asieris. ” About Photocure ASA.

Licensing 40

Licensing Licensing Clinical Development Pharmaceutical Companies 40

The Pharma Data

MARCH 16, 2021

By combining our expertise, we hope to make significant steps forward to finding solutions for patients for which there currently is no treatment.”. In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders.

Licensing 52

Licensing Licensing Research Laboratories Pharmaceutical Companies 52

The Pharma Data

JANUARY 19, 2021

The event will feature a presentation by renowned lymphoma expert Mats Jerkeman, MD, Lund University, who will discuss the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin’s Lymphoma for whom current treatment options are very limited.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

DECEMBER 9, 2020

Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody ® -based therapeutics against certain targets selected by Takeda. About Crescendo Biologics Crescendo Biologics is a clinical stage T cell enhancing company. – Ends-.

Licensing 52

Licensing Licensing Pharmaceutical Companies Engineering 52

The Pharma Data

DECEMBER 8, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively.

Clinical Trials 40

Clinical Trials International Licensing Licensing 40

The Pharma Data

NOVEMBER 10, 2020

The poster presentation, given by Johan Sandin , CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease. . STOCKHOLM , Nov. About AlzeCure Pharma AB (publ).

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. and are linked to the company’s project AD1503.

Disease 40

Disease Pharmaceutical Companies Licensing Licensing 40

The Pharma Data

OCTOBER 14, 2020

. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. Drug Enforcement Administration. Jacobs , Harmony’s President and Chief Executive Officer.

FDA Approval 52

FDA Approval FDA Treatment Pharmaceutical Companies 52